We are using cookies to implement functions like login, shopping cart or language selection for this website and to create anonymized statistical reports of the usage. You will find more information in our privacy policy. OK, I have understood
International Poster Journal of Dentistry and Oral Medicine
Login:
username:

password:

Plattform:

Forgotten password?

Registration

Int Poster J Dent Oral Med 4 (2002), No. 1     15. Mar. 2002
Int Poster J Dent Oral Med 4 (2002), No. 1  (15.03.2002)

Poster 111, Language: German


Neuartiger Therapieansatz einer oralen Papillomatose bei HIV-Infektion mit Imiquimod - Ein Fallbericht
Horodko, Martin/Schöfer, Helmut/Ratka-Krüger, Petra/Raetzke, Peter
In this case report we introduce a 38-year old HIV-infected (stage B3, CDC) male with distinct oral lesions. The patient was diagnosed HIV positive in 1985 and is currently under treatment with Abacavir, Lamivudin and Zidovudin. During this therapy, the HIV virus has been suppressed below detectibility, and a gain of CD4-cells to 250 cells/µl has been observed. A single course of herpes zoster infection has occurred 5 years ago; genital herpes recurs in irregular intervals.
According to the patient's medical history, first gingival overgrowth was noticed about one year ago. It occurred in the region of the lower anterior teeth, including the canines and first cuspids. We found hypertrophic alterations with cleft surfaces on the facial and oral aspects of the gingival tissues. Solitary papules of 6 mm in diameter existed on the edentulous site of the missing first lower left molar, on the mucosa of the lower lip, and on the vestibular gingival papilla between the upper right canine and lateral incisor. Biopsies were taken, and the histological findings confirmed the clinical presumption of an oral papillomatosis. Also, HPV-6 was identified by PCR virus typing.
With the patient's informed consent, the oral papillomatosis was treated with Imiquimod 5% cream, which is licensed for the treatment of genito-anal papillomata. It was applied twice a week for a duration of 4 weeks. Since no immediate success was detected, the decision was made to extend the treatment for another 4 weeks, 3 times weekly. After a total of 8 weeks into treatment, a complete remission had occurred. This result seems to be stable, since no recurrence was seen up to eight months after therapy. Also, there were no side-effects during the total period of observation. It remains to be seen whether this treatment result is preserved over a longer period of time.

Keywords: Orale Papillomatose, HIV, Imiquimod

Conference/Exhibition:
06. - 07.07.2001
Interdisziplinäres Symposium des Arbeitskreises Oralpathologie und Oralmedizin und der Arbeitsgemeinschaft Dermatologische Infektiologie (ADI) der Deutschen Dermatologischen Gesellschaft (DDG): Virusinfektionen und Tumoren der oralen Schleimhaut
Rostock